Iason GmbH has continued its refinancing efforts with local banks based on an IBR
The shareholders of Iason GmbH have completed a restructuring of the company and its refinancing efforts with local banks based on an IBR.
The Iason group produces radiopharmaceuticals and supplies special laboratory products to the target group "nuclear medicine" and "laboratory medicine" providing innovative products with the highest quality standards. The company has customers from all over Europe.
Oaklins' team in Austria assisted Iason with the preparation of the IBR (independent business review) and negotiations with local banks regarding refinancing possibilities.
Sprechen Sie mit dem Deal-Team
Thomas Jungreithmeir
Oaklins Austria
Relevante Transaktionen
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Weitere InformationenbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Weitere InformationenSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Weitere Informationen